Darwin Global Management, Ltd. - 27 Jun 2023 Form 4 Insider Report for Ambrx Biopharma Inc.

Reporting relationship: 10%+ Owner
Issuer ticker: N/A
Reported as of: 27 Jun 2023
Net transaction value: +$74,999,998
SEC form: 4
Accepted by SEC: 28 Jun 2023, 16:45:44 UTC
Prior SEC filing: 08 Mar 2023
Source filing: View source filing
Reporting owner signature: Darwin Global Management, Ltd. By: /s/ John Legge, Director and Chief Financial Officer

Key filing fact

Darwin Global Management, Ltd. filed Form 4 for Ambrx Biopharma Inc. on 28 Jun 2023.

Key facts

This page summarizes Darwin Global Management, Ltd.'s Form 4 filing for Ambrx Biopharma Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Jun 2023, 16:45.

Change

Previous filing in this sequence was filed on 08 Mar 2023.
Current net transaction value: +$74,999,998.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMAM transaction Derivative

American Depository Shares ("ADSs")

Purchase

Transaction value: $74,999,998
Shares: +5,384,063
Change %: +48%
Price: $13.93
Shares after: 16,688,636
Date: 27 Jun 2023
Ownership: See footnotes
Underlying class: Ordinary Shares
Underlying amount: 37,688,441
Exercise price: $0.000000
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each ADS represents 7 ordinary shares, par value $0.0001 per share ("Ordinary Shares").

Footnote F2

Securities held for the accounts of certain investment funds and accounts for which Darwin Global Management, Ltd. ("Darwin Global") acts as investment manager, including Darwin Global Master Fund, Ltd. ("Master Fund"). The sole shareholder of Darwin Global is controlled by Dr. Abhishek Trehan ("Dr. Trehan").

Footnote F3

For purposes of Section 16 of the Securities Exchange Act of 1934, each of Darwin Global, Master Fund and Dr. Trehan expressly disclaims neficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that any of Darwin Global, Master Fund or Dr. Trehan is the beneficial owner of such securities for purposes of Section 16 or any other purpose.